Biologische Therapien und Krebs - the European Oncology Nursing ...

8
Foss FM, Saleh MN, Krueger JG, et al. Diphtheria toxin fusion proteins. In: Frankel AE, editor. Clinical
applications of immunotoxins. Berlin: Springer Verlag, 1998:63–81.
Grossbard ML, editor. Monoclonal antibody-based therapy of cancer. New York:
Marcel Dekker, 1998.
Hertler AA, Frankel AE. Immunotoxins: a clinical review of their use in the treatment of malignancies.
J Clin Oncol 1989;7:1932–42.
Jurcic JG, Scheinberg DA. Radioimmunotherapy of hematological cancer: problems and prognosis.
Clin Cancer Res 1995;1:533–41.
McDevitt MR, Sgouros G, Finn RD, et al. Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med
1998;25:1341–51.
MacLean JA, Su Z, Guo Y, et al. Anti-CD3: anti-IL-2 receptor bispecific monoclonal antibody.
J Immunol 1993;150:1619–28.
Meredith RF, LoBuglio AF, Spencer EB. Recent progress in radioimmunotherapy for cancer. Oncology
1997;11:979–84.
Osoba D, Burchmore M. Health-related quality of life in women with metastatic breast cancer treated with
trastuzumab (Herceptin). Semin Oncol 1999;26(Suppl. 12):84–8.
Piccart MJ, Di Leo A, Hamilton A. HER2: a ‘predictive factor’ ready to use in the daily management of
breast cancer patients? Eur J Cancer 2000;36:1755–61.
Sgouros G. Radioimmunotherapy of micrometastases: sidestepping the solid tumor hurdle. J Nucl Med
1995;36:1910–12.
Slamon DJ, Leyland-Jones B, Shak S, et al. Concurrent administration of anti-HER-2 monoclonal antibody
and first-line chemotherapy for HER2-overexpressing metastatic breast cancer: a phase III, multinational,
randomized, controlled trial. N Engl J Med 2001, in press.
Uckun FM, Reaman GH. Immunotoxins for treatment of leukemia and lymphoma. Leuk Lymphoma
1995;18:195–201.
Valone FH, Kaufman PA, Guyre PM, et al. Clinical trials of bispecific antibody MDX-210 in women with
advanced breast or ovarian cancer that overexpress HER-2/neu. J Hematol 1995a;4:471–5.
Winkler U, Barth S, Schnell R, et al. The emerging role of immunotoxins in leukemia and lymphoma.
Ann Oncol 1997;1(Suppl.):139–46.
Krebs-Impfungen
Disis ML, Cheever MA. HER-2/neu oncogenic protein: issues in vaccine development. Crit Rev Immunol
1998;18:37–45.
Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide or tumor lysate-pulsed
dendritic cells. Nat Med 1998;4:328–32.
Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic
vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4:321.
Stern PL, Beverley PCL, Carroll MW, editors. Cancer vaccines and immunotherapy. Cambridge: Cambridge
University Press, 2000.
Tindle RW. Human papillomavirus vaccines for cervical cancer. Curr Opin Immunol 1998;8:643.
8.30